Pharmacology and therapeutic implications of current drugs for type 2 diabetes mellitus

[1]  André Rodrigues,et al.  Mellitus , 2018, Proceedings of the 17th International Conference on Mobile and Ubiquitous Multimedia.

[2]  Exenatide , 2018, Reactions Weekly.

[3]  Deepak L. Bhatt,et al.  Cardiovascular Outcomes According to Urinary Albumin and Kidney Disease in Patients With Type 2 Diabetes at High Cardiovascular Risk: Observations From the SAVOR-TIMI 53 Trial , 2017, JAMA cardiology.

[4]  M. Delgado-Rodríguez,et al.  Systematic review and meta-analysis. , 2017, Medicina intensiva.

[5]  S. Engel,et al.  A randomized, placebo‐ and sitagliptin‐controlled trial of the safety and efficacy of omarigliptin, a once‐weekly dipeptidyl peptidase‐4 inhibitor, in Japanese patients with type 2 diabetes , 2017, Diabetes, obesity & metabolism.

[6]  藤倉雄二,et al.  わが国における成人市中肺炎の原因微生物の変遷(Meta‐analysis and systematic review) , 2017 .

[7]  A. de Laat,et al.  Network meta-analysis. , 2017, Journal of oral rehabilitation.

[8]  M. Bonab.  randomised trial , 2022 .

[9]  R. Henry,et al.  Efficacy and Tolerability of Exenatide Once Weekly Over 6 Years in Patients with Type 2 Diabetes: An Uncontrolled Open-Label Extension of the DURATION-1 Study , 2016, Diabetes technology & therapeutics.

[10]  M. Hanefeld,et al.  Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial , 2016, Diabetes Care.

[11]  M. Rizzo,et al.  Once-Daily Liraglutide Versus Lixisenatide as Add-on to Metformin in Type 2 Diabetes: A 26-Week Randomized Controlled Clinical Trial , 2016, Diabetes Care.

[12]  H. Lebovitz,et al.  Comparative review of dipeptidyl peptidase‐4 inhibitors and sulphonylureas , 2016, Diabetes, obesity & metabolism.

[13]  M. Fischereder,et al.  Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes. , 2016, The New England journal of medicine.

[14]  W. Han,et al.  Pancreatic regulation of glucose homeostasis , 2016, Experimental & Molecular Medicine.

[15]  J. Rungby,et al.  Diabetic Ketoacidosis in a Patient with Type 2 Diabetes After Initiation of Sodium–Glucose Cotransporter 2 Inhibitor Treatment , 2016, Basic & clinical pharmacology & toxicology.

[16]  K. Mahaffey,et al.  Efficacy and safety of canagliflozin when used in conjunction with incretin‐mimetic therapy in patients with type 2 diabetes , 2016, Diabetes, obesity & metabolism.

[17]  Xinghuan Wang,et al.  The impact of surgical treatments for lower urinary tract symptoms/benign prostatic hyperplasia on male erectile function , 2016, Medicine.

[18]  N. Watts,et al.  Evaluation of Bone Mineral Density and Bone Biomarkers in Patients With Type 2 Diabetes Treated With Canagliflozin. , 2016, The Journal of clinical endocrinology and metabolism.

[19]  N. Watts,et al.  Effects of Canagliflozin on Fracture Risk in Patients With Type 2 Diabetes Mellitus. , 2016, The Journal of clinical endocrinology and metabolism.

[20]  S. Solomon,et al.  Lixisenatide in Patients with Type 2 Diabetes and Acute Coronary Syndrome. , 2015, The New England journal of medicine.

[21]  Pavel S. Roshanov,et al.  Incretin-based therapies are associated with acute pancreatitis: Meta-analysis of large randomized controlled trials. , 2015, Diabetes research and clinical practice.

[22]  U. Broedl,et al.  Empagliflozin as add‐on to metformin in people with Type 2 diabetes , 2015, Diabetic medicine : a journal of the British Diabetic Association.

[23]  A. Chang,et al.  Randomized Clinical Trial Comparing Basal Insulin Peglispro and Insulin Glargine in Patients With Type 2 Diabetes Previously Treated With Basal Insulin: IMAGINE 5 , 2015, Diabetes Care.

[24]  D. Matthews,et al.  Efficacy and safety of once‐weekly glucagon‐like peptide 1 receptor agonists for the management of type 2 diabetes: a systematic review and meta‐analysis of randomized controlled trials , 2015, Diabetes, obesity & metabolism.

[25]  Celeste B. Burness.  Omarigliptin: First Global Approval , 2015, Drugs.

[26]  S. Zhan,et al.  Impact of GLP-1 receptor agonists on blood pressure, heart rate and hypertension among patients with type 2 diabetes: A systematic review and network meta-analysis. , 2015, Diabetes research and clinical practice.

[27]  U. Broedl,et al.  Empagliflozin as add-on to metformin plus sulphonylurea in patients with type 2 diabetes. , 2015, Diabetes research and clinical practice.

[28]  J. Rosenstock,et al.  Efficacy and safety of liraglutide versus placebo added to basal insulin analogues (with or without metformin) in patients with type 2 diabetes: a randomized, placebo‐controlled trial , 2015, Diabetes, obesity & metabolism.

[29]  S. Atkin,et al.  A Phase 2, Randomized, Dose-Finding Study of the Novel Once-Weekly Human GLP-1 Analog, Semaglutide, Compared With Placebo and Open-Label Liraglutide in Patients With Type 2 Diabetes , 2015, Diabetes Care.

[30]  R. DeFronzo,et al.  Impact of glucose-lowering drugs on cardiovascular disease in type 2 diabetes. , 2015, European heart journal.

[31]  H. Yang,et al.  Efficacy and Safety of Bromocriptine-QR in Type 2 Diabetes: A Systematic Review and Meta-Analysis , 2015, Hormone and Metabolic Research.

[32]  V. Pechtner,et al.  Treatment satisfaction in people with type 2 diabetes mellitus treated with once‐weekly dulaglutide: data from the AWARD‐1 and AWARD‐3 clinical trials , 2015, Diabetes, obesity & metabolism.

[33]  E. Vittinghoff,et al.  Effects of TZD Use and Discontinuation on Fracture Rates in ACCORD Bone Study. , 2015, The Journal of clinical endocrinology and metabolism.

[34]  N. Tong,et al.  Therapeutic potential of α-glucosidase inhibitors in type 2 diabetes mellitus: an evidence-based review , 2015, Expert opinion on pharmacotherapy.

[35]  J. Rosenstock,et al.  Euglycemic Diabetic Ketoacidosis: A Predictable, Detectable, and Preventable Safety Concern With SGLT2 Inhibitors , 2015, Diabetes Care.

[36]  R. DeFronzo,et al.  The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation: Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies , 2015, Diabetes Care.

[37]  C. Bailey.  The Current Drug Treatment Landscape for Diabetes and Perspectives for the Future , 2015, Clinical pharmacology and therapeutics.

[38]  C. Kovacs,et al.  Empagliflozin as Add-on Therapy to Pioglitazone With or Without Metformin in Patients With Type 2 Diabetes Mellitus. , 2015, Clinical therapeutics.

[39]  G. Nucci,et al.  Blood pressure‐lowering effect of the sodium glucose co‐transporter‐2 inhibitor ertugliflozin, assessed via ambulatory blood pressure monitoring in patients with type 2 diabetes and hypertension , 2015, Diabetes, obesity & metabolism.

[40]  D. Tarng,et al.  Metformin use and mortality in patients with advanced chronic kidney disease: national, retrospective, observational, cohort study. , 2015, The lancet. Diabetes & endocrinology.

[41]  G. Meininger,et al.  Diabetic Ketoacidosis and Related Events in the Canagliflozin Type 2 Diabetes Clinical Program , 2015, Diabetes Care.

[42]  E. Ferrannini,et al.  Energy Balance After Sodium–Glucose Cotransporter 2 Inhibition , 2015, Diabetes Care.

[43]  M. Pencina,et al.  Effect of Sitagliptin on Cardiovascular Outcomes in Type 2 Diabetes. , 2015, The New England journal of medicine.

[44]  J. Rosenstock,et al.  Impact of empagliflozin added on to basal insulin in type 2 diabetes inadequately controlled on basal insulin: a 78‐week randomized, double‐blind, placebo‐controlled trial , 2015, Diabetes, obesity & metabolism.

[45]  S. Kalra,et al.  Sodium glucose transporter 2 (SGLT2) inhibition and ketogenesis , 2015, Indian journal of endocrinology and metabolism.

[46]  S. Gough,et al.  One‐year efficacy and safety of a fixed combination of insulin degludec and liraglutide in patients with type 2 diabetes: results of a 26‐week extension to a 26‐week main trial , 2015, Diabetes, obesity & metabolism.

[47]  K. Khunti,et al.  The Effect of Glucagon-Like Peptide 1 Receptor Agonists on Weight Loss in Type 2 Diabetes: A Systematic Review and Mixed Treatment Comparison Meta-Analysis , 2015, PloS one.

[48]  K. McKeage.  Trelagliptin: First Global Approval , 2015, Drugs.

[49]  A. Grey,et al.  The effect of thiazolidinediones on bone mineral density and bone turnover: systematic review and meta-analysis , 2015, Diabetologia.

[50]  F. Giorgino,et al.  Efficacy and Safety of Once-Weekly Dulaglutide Versus Insulin Glargine in Patients With Type 2 Diabetes on Metformin and Glimepiride (AWARD-2) , 2015, Diabetes Care.

[51]  I. Hirsch,et al.  Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium–Glucose Cotransporter 2 Inhibition , 2015, Diabetes Care.

[52]  J. Foley,et al.  Comparison of vildagliptin and sitagliptin in patients with type 2 diabetes and severe renal impairment: a randomised clinical trial , 2015, Diabetologia.

[53]  D. Reda,et al.  Follow-up of glycemic control and cardiovascular outcomes in type 2 diabetes. , 2015, The New England journal of medicine.

[54]  Erratum to GLP-1 receptor agonists: a review of head-to-head clinical studies , 2015, Therapeutic advances in endocrinology and metabolism.

[55]  H. Sakoda,et al.  Effects of Miglitol, Acarbose, and Sitagliptin on Plasma Insulin and Gut Peptides in Type 2 Diabetes Mellitus: A Crossover Study , 2015, Diabetes Therapy.

[56]  G. Nucci,et al.  Dose‐ranging efficacy and safety study of ertugliflozin, a sodium‐glucose co‐transporter 2 inhibitor, in patients with type 2 diabetes on a background of metformin , 2015, Diabetes, obesity & metabolism.

[57]  D. Drucker,et al.  Islet α cells and glucagon—critical regulators of energy homeostasis , 2015, Nature Reviews Endocrinology.

[58]  L. Blonde,et al.  Once-weekly dulaglutide versus bedtime insulin glargine, both in combination with prandial insulin lispro, in patients with type 2 diabetes (AWARD-4): a randomised, open-label, phase 3, non-inferiority study , 2015, The Lancet.

[59]  G. Umpierrez,et al.  Safety and efficacy of once‐weekly dulaglutide versus sitagliptin after 2 years in metformin‐treated patients with type 2 diabetes (AWARD‐5): a randomized, phase III study , 2015, Diabetes, obesity & metabolism.

[60]  L. V. Van Gaal,et al.  Weight Management in Type 2 Diabetes: Current and Emerging Approaches to Treatment , 2015, Diabetes Care.

[61]  C. White,et al.  Comparative Efficacy and Safety of Antidiabetic Drug Regimens Added to Metformin Monotherapy in Patients with Type 2 Diabetes: A Network Meta-Analysis , 2015, PloS one.

[62]  F. Pattou,et al.  Inhibition of the glucose transporter SGLT2 with dapagliflozin in pancreatic alpha cells triggers glucagon secretion , 2015, Nature Medicine.

[63]  J. Rosenstock,et al.  Contrasting Effects of Lixisenatide and Liraglutide on Postprandial Glycemic Control, Gastric Emptying, and Safety Parameters in Patients With Type 2 Diabetes on Optimized Insulin Glargine With or Without Metformin: A Randomized, Open-Label Trial , 2015, Diabetes Care.

[64]  M. Rendell,et al.  Glucagon-like polypeptide agonists in type 2 diabetes mellitus: efficacy and tolerability, a balance , 2015, Therapeutic advances in endocrinology and metabolism.

[65]  A. Tahrani,et al.  Novel therapeutics for type 2 diabetes: insulin resistance , 2015, Diabetes, obesity & metabolism.

[66]  N. Inagaki,et al.  Once-weekly trelagliptin versus daily alogliptin in Japanese patients with type 2 diabetes: a randomised, double-blind, phase 3, non-inferiority study. , 2015, The lancet. Diabetes & endocrinology.

[67]  P. Light,et al.  Comparative cardiovascular safety of insulin secretagogues following hospitalization for ischemic heart disease among type 2 diabetes patients: a cohort study. , 2015, Journal of diabetes and its complications.

[68]  M. Trautmann,et al.  Five-year efficacy and safety data of exenatide once weekly: long-term results from the DURATION-1 randomized clinical trial. , 2015, Mayo Clinic proceedings.

[69]  B. Ahrén,et al.  DPP-4 inhibition contributes to the prevention of hypoglycaemia through a GIP–glucagon counterregulatory axis in mice , 2015, Diabetologia.

[70]  Kira B. Harris,et al.  Efficacy and tolerability of glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus , 2015, Therapeutic advances in endocrinology and metabolism.

[71]  M. Stewart,et al.  Efficacy and tolerability of albiglutide versus placebo or pioglitazone over 1 year in people with type 2 diabetes currently taking metformin and glimepiride: HARMONY 5 , 2015, Diabetes, obesity & metabolism.

[72]  Jennifer M. Trujillo,et al.  GLP-1 receptor agonists: a review of head-to-head clinical studies , 2015, Therapeutic advances in endocrinology and metabolism.

[73]  D. Giugliano,et al.  A nomogram to estimate the HbA1c response to different DPP-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of 98 trials with 24 163 patients , 2015, BMJ Open.

[74]  S. Matthaei,et al.  Dapagliflozin Improves Glycemic Control and Reduces Body Weight as Add-on Therapy to Metformin Plus Sulfonylurea: A 24-Week Randomized, Double-Blind Clinical Trial , 2015, Diabetes Care.

[75]  S. Zhai,et al.  Using real‐world data to evaluate the association of incretin‐based therapies with risk of acute pancreatitis: a meta‐analysis of 1 324 515 patients from observational studies , 2015, Diabetes, obesity & metabolism.

[76]  B. Zinman,et al.  Glucagon-like peptide-1 receptor agonist and basal insulin combination treatment for the management of type 2 diabetes: a systematic review and meta-analysis , 2014, The Lancet.

[77]  C. Bailey,et al.  Pharmacotherapies to manage diabesity: an update , 2015 .

[78]  A. W. Hitchings,et al.  Safety of Metformin in Patients with Chronic Obstructive Pulmonary Disease and Type 2 Diabetes Mellitus , 2015, COPD.

[79]  S. Zhan,et al.  Effect of glucagon-like peptide-1 receptor agonists on lipid profiles among type 2 diabetes: a systematic review and network meta-analysis. , 2015, Clinical therapeutics.

[80]  M. Islam.  Islets of Langerhans , 2015, Springer Netherlands.

[81]  M. Okano,et al.  Cohort Study , 2020, Definitions.

[82]  Y. Zhang,et al.  Effect of GLP-1 receptor agonists on waist circumference among type 2 diabetes patients: a systematic review and network meta-analysis , 2015, Endocrine.

[83]  C. Sacerdote,et al.  Incretin-based therapies and acute pancreatitis risk: a systematic review and meta-analysis of observational studies , 2015, Endocrine.

[84]  Deepak L. Bhatt,et al.  Saxagliptin and Cardiovascular Outcomes in Patients With Type 2 Diabetes and Moderate or Severe Renal Impairment: Observations From the SAVOR-TIMI 53 Trial , 2014, Diabetes Care.

[85]  C. Palmer,et al.  Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study , 2014, Diabetes.

[86]  D. Matthews,et al.  Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes , 2014, Diabetes Care.

[87]  K. Mahaffey,et al.  Efficacy and Safety of Canagliflozin, an Inhibitor of Sodium–Glucose Cotransporter 2, When Used in Conjunction With Insulin Therapy in Patients With Type 2 Diabetes , 2014, Diabetes Care.

[88]  J. Reusch,et al.  Efficacy and safety of once‐weekly glucagon‐like peptide 1 receptor agonist albiglutide (HARMONY 1 trial): 52‐week primary endpoint results from a randomized, double‐blind, placebo‐controlled trial in patients with type 2 diabetes mellitus not controlled on pioglitazone, with or without metformin , 2014, Diabetes, obesity & metabolism.

[89]  S. Del Prato,et al.  Durability of glycaemic efficacy over 2 years with dapagliflozin versus glipizide as add‐on therapies in patients whose type 2 diabetes mellitus is inadequately controlled with metformin , 2014, Diabetes, obesity & metabolism.

[90]  P. Gourdy,et al.  Lixisenatide as add‐on to oral anti‐diabetic therapy: an effective treatment for glycaemic control with body weight benefits in type 2 diabetes , 2014, Diabetes/metabolism research and reviews.

[91]  H. Tian,et al.  Lixisenatide treatment improves glycaemic control in Asian patients with type 2 diabetes mellitus inadequately controlled on metformin with or without sulfonylurea: a randomized, double‐blind, placebo‐controlled, 24‐week trial (GetGoal‐M‐Asia) , 2014, Diabetes/metabolism research and reviews.

[92]  T. Heise,et al.  Effect of the sodium glucose co‐transporter 2 inhibitor canagliflozin on plasma volume in patients with type 2 diabetes mellitus , 2014, Diabetes, obesity & metabolism.

[93]  F. Tinahones,et al.  Lixisenatide plus basal insulin in patients with type 2 diabetes mellitus: a meta-analysis. , 2014, Journal of diabetes and its complications.

[94]  S. Gough,et al.  Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide (IDegLira) compared with its components given alone: results of a phase 3, open-label, randomised, 26-week, treat-to-target trial in insulin-naive patients with type 2 diabetes. , 2014, The lancet. Diabetes & endocrinology.

[95]  E. Ferrannini,et al.  The target of metformin in type 2 diabetes. , 2014, The New England journal of medicine.

[96]  J. Fahrbach,et al.  Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial , 2014, The Lancet.

[97]  A. Barnett,et al.  Empagliflozin for the treatment of type 2 diabetes , 2014, Expert opinion on pharmacotherapy.

[98]  H. Rodbard,et al.  Contribution of Liraglutide in the Fixed-Ratio Combination of Insulin Degludec and Liraglutide (IDegLira) , 2014, Diabetes Care.

[99]  S. Hahn,et al.  Differences in the HbA1c‐lowering efficacy of glucagon‐like peptide‐1 analogues between Asians and non‐Asians: a systematic review and meta‐analysis , 2014, Diabetes, obesity & metabolism.

[100]  L. Morrow,et al.  Canagliflozin, a sodium glucose co-transporter 2 inhibitor, reduces post-meal glucose excursion in patients with type 2 diabetes by a non-renal mechanism: results of a randomized trial. , 2014, Metabolism: clinical and experimental.

[101]  E. Lonn,et al.  Effects of the Once-Weekly Glucagon-Like Peptide-1 Receptor Agonist Dulaglutide on Ambulatory Blood Pressure and Heart Rate in Patients With Type 2 Diabetes Mellitus , 2014, Hypertension.

[102]  I. Tikkanen,et al.  Empagliflozin Reduces Blood Pressure in Patients With Type 2 Diabetes and Hypertension , 2014, Diabetes Care.

[103]  R. Pratley,et al.  HARMONY 4: randomised clinical trial comparing once-weekly albiglutide and insulin glargine in patients with type 2 diabetes inadequately controlled with metformin with or without sulfonylurea , 2014, Diabetologia.

[104]  Lawrence A. Leiter,et al.  Canagliflozin Provides Durable Glycemic Improvements and Body Weight Reduction Over 104 Weeks Versus Glimepiride in Patients With Type 2 Diabetes on Metformin: A Randomized, Double-Blind, Phase 3 Study , 2014, Diabetes Care.

[105]  L. Schmidt,et al.  A systematic review and meta‐analysis of the efficacy of lixisenatide in the treatment of patients with type 2 diabetes , 2014, Diabetes, obesity & metabolism.

[106]  R. Berria,et al.  Pronounced reduction of postprandial glucagon by lixisenatide: a meta‐analysis of randomized clinical trials , 2014, Diabetes, obesity & metabolism.

[107]  S. Yusuf,et al.  Impact of rosiglitazone on body composition, hepatic fat, fatty acids, adipokines and glucose in persons with impaired fasting glucose or impaired glucose tolerance: a sub‐study of the DREAM trial , 2014, Diabetic medicine : a journal of the British Diabetic Association.

[108]  M. Ridderstråle,et al.  Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial. , 2014, The lancet. Diabetes & endocrinology.

[109]  Xuping Yang,et al.  Efficacy and safety of canagliflozin in subjects with type 2 diabetes: systematic review and meta-analysis , 2014, European Journal of Clinical Pharmacology.

[110]  A. Apanovitch,et al.  Safety Profile of Dapagliflozin for Type 2 Diabetes: Pooled Analysis of Clinical Studies for Overall Safety and Rare Events , 2014, Drug Safety.

[111]  J. Chien,et al.  Dose‐finding results in an adaptive, seamless, randomized trial of once‐weekly dulaglutide combined with metformin in type 2 diabetes patients (AWARD‐5) , 2014, Diabetes, obesity & metabolism.

[112]  J. Rosenstock,et al.  Efficacy and Safety of Colesevelam in Combination with Pioglitazone in Patients with Type 2 Diabetes Mellitus , 2014, Hormone and Metabolic Research.

[113]  Diane M. Miller,et al.  Advancing Basal Insulin Replacement in Type 2 Diabetes Inadequately Controlled With Insulin Glargine Plus Oral Agents: A Comparison of Adding Albiglutide, a Weekly GLP-1 Receptor Agonist, Versus Thrice-Daily Prandial Insulin Lispro , 2014, Diabetes Care.

[114]  G. Colon,et al.  Efficacy and Safety of Dulaglutide Added Onto Pioglitazone and Metformin Versus Exenatide in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-1) , 2014, Diabetes Care.

[115]  G. Umpierrez,et al.  Efficacy and Safety of Dulaglutide Monotherapy Versus Metformin in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-3) , 2014, Diabetes Care.

[116]  G. Umpierrez,et al.  Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5) , 2014, Diabetes Care.

[117]  R. Holman,et al.  Rationale for and design of the Acarbose Cardiovascular Evaluation (ACE) trial. , 2014, American heart journal.

[118]  S. Grandy,et al.  Changes in weight loss‐related quality of life among type 2 diabetes mellitus patients treated with dapagliflozin , 2014, Diabetes, obesity & metabolism.

[119]  W. van Biesen,et al.  Glucose-lowering drugs in patients with chronic kidney disease: a narrative review on pharmacokinetic properties. , 2014, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[120]  J. Dixon,et al.  A randomized controlled trial of the effects of pioglitazone treatment on sympathetic nervous system activity and cardiovascular function in obese subjects with metabolic syndrome. , 2014, The Journal of clinical endocrinology and metabolism.

[121]  J. Rosenstock,et al.  Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes , 2014, Diabetes Care.

[122]  H. Zimdahl,et al.  Influence of TCF7L2 gene variants on the therapeutic response to the dipeptidylpeptidase-4 inhibitor linagliptin , 2014, Diabetologia.

[123]  M. Feinglos,et al.  HARMONY 3: 104-Week Randomized, Double-Blind, Placebo- and Active-Controlled Trial Assessing the Efficacy and Safety of Albiglutide Compared With Placebo, Sitagliptin, and Glimepiride in Patients With Type 2 Diabetes Taking Metformin , 2014, Diabetes Care.

[124]  Luc Van Gaal,et al.  Exenatide once weekly versus insulin glargine for type 2 diabetes (DURATION-3): 3-year results of an open-label randomised trial. , 2014, The lancet. Diabetes & endocrinology.

[125]  J. Heaf.  Metformin in Chronic Kidney Disease: Time for a Rethink , 2014, Peritoneal Dialysis International.

[126]  D. Giugliano,et al.  Glycaemic durability with dipeptidyl peptidase-4 inhibitors in type 2 diabetes: a systematic review and meta-analysis of long-term randomised controlled trials , 2014, BMJ Open.

[127]  Michael J. MacDonald,et al.  Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase , 2014, Nature.

[128]  H. Häring,et al.  Empagliflozin as Add-On to Metformin in Patients With Type 2 Diabetes: A 24-Week, Randomized, Double-Blind, Placebo-Controlled Trial , 2014, Diabetes Care.

[129]  P. Home,et al.  Insulin Therapy in People With Type 2 Diabetes: Opportunities and Challenges? , 2014, Diabetes Care.

[130]  B. Wagner,et al.  Inhibition of HDAC3 as a strategy for developing novel diabetes therapeutics. , 2014, Epigenomics.

[131]  U. Broedl,et al.  Empagliflozin improves glycemic parameters and cardiovascular risk factors in patients with Type 2 Diabetes (T2DM): Pooled data from four pivotal phase III trials , 2014 .

[132]  M. Hanefeld,et al.  Beneficial effects of once-daily lixisenatide on overall and postprandial glycemic levels without significant excess of hypoglycemia in type 2 diabetes inadequately controlled on a sulfonylurea with or without metformin (GetGoal-S). , 2014, Journal of diabetes and its complications.

[133]  A. Mithal,et al.  Efficacy and safety of empagliflozin added to existing antidiabetes treatment in patients with type 2 diabetes and chronic kidney disease: a randomised, double-blind, placebo-controlled trial. , 2014, The lancet. Diabetes & endocrinology.

[134]  G. Guyatt,et al.  Incretin treatment and risk of pancreatitis in patients with type 2 diabetes mellitus: systematic review and meta-analysis of randomised and non-randomised studies , 2014, BMJ : British Medical Journal.

[135]  Kathy Lyons,et al.  Omarigliptin (MK-3102): a novel long-acting DPP-4 inhibitor for once-weekly treatment of type 2 diabetes. , 2014, Journal of medicinal chemistry.

[136]  S. Leung,et al.  The efficacy of dapagliflozin combined with hypoglycaemic drugs in treating type 2 diabetes mellitus: meta-analysis of randomised controlled trials , 2014, BMJ Open.

[137]  Murray Stewart,et al.  Once-weekly albiglutide versus once-daily liraglutide in patients with type 2 diabetes inadequately controlled on oral drugs (HARMONY 7): a randomised, open-label, multicentre, non-inferiority phase 3 study. , 2014, The lancet. Diabetes & endocrinology.

[138]  Weiqing Wang,et al.  Head‐to‐head comparison of dipeptidyl peptidase‐IV inhibitors and sulfonylureas – a meta‐analysis from randomized clinical trials , 2014, Diabetes/metabolism research and reviews.

[139]  B. Hummer,et al.  Pancreatic safety of incretin-based drugs--FDA and EMA assessment. , 2014, The New England journal of medicine.

[140]  P. Nyirjesy,et al.  Genital mycotic infections with canagliflozin, a sodium glucose co-transporter 2 inhibitor, in patients with type 2 diabetes mellitus: a pooled analysis of clinical studies , 2014, Current medical research and opinion.

[141]  E. Bass,et al.  The Pharmacogenetics of Type 2 Diabetes: A Systematic Review , 2014, Diabetes Care.

[142]  R. DeFronzo,et al.  Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production. , 2014, The Journal of clinical investigation.

[143]  T. Heise,et al.  Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients. , 2014, The Journal of clinical investigation.

[144]  C. Kovacs,et al.  Empagliflozin improves glycaemic and weight control as add‐on therapy to pioglitazone or pioglitazone plus metformin in patients with type 2 diabetes: a 24‐week, randomized, placebo‐controlled trial , 2014, Diabetes, obesity & metabolism.

[145]  M. Hanefeld,et al.  Efficacy and safety of lixisenatide once daily vs. placebo in people with Type 2 diabetes insufficiently controlled on metformin (GetGoal‐F1) , 2014, Diabetic medicine : a journal of the British Diabetic Association.

[146]  A. Scheen.  Drug–Drug Interactions with Sodium-Glucose Cotransporters Type 2 (SGLT2) Inhibitors, New Oral Glucose-Lowering Agents for the Management of Type 2 Diabetes Mellitus , 2014, Clinical Pharmacokinetics.

[147]  A. Scheen.  Pharmacodynamics, Efficacy and Safety of Sodium–Glucose Co-Transporter Type 2 (SGLT2) Inhibitors for the Treatment of Type 2 Diabetes Mellitus , 2014, Drugs.

[148]  Wenying Yang,et al.  Acarbose compared with metformin as initial therapy in patients with newly diagnosed type 2 diabetes: an open-label, non-inferiority randomised trial. , 2014, The lancet. Diabetes & endocrinology.

[149]  R. Brook,et al.  Effect of GLP-1 mimetics on blood pressure and relationship to weight loss and glycemia lowering: results of a systematic meta-analysis and meta-regression. , 2014, American Journal of Hypertension.

[150]  D. Owens,et al.  Differential effects of GLP-1 receptor agonists on components of dysglycaemia in individuals with type 2 diabetes mellitus. , 2013, Diabetes & metabolism.

[151]  M. Roden,et al.  Empagliflozin monotherapy with sitagliptin as an active comparator in patients with type 2 diabetes: a randomised, double-blind, placebo-controlled, phase 3 trial. , 2013, The lancet. Diabetes & endocrinology.

[152]  R. Aronson,et al.  Efficacy and safety of lixisenatide once daily versus placebo in type 2 diabetes insufficiently controlled on pioglitazone (GetGoal‐P) , 2013, Diabetes, obesity & metabolism.

[153]  H. Häring,et al.  Empagliflozin as Add-on to Metformin Plus Sulfonylurea in Patients With Type 2 Diabetes , 2013, Diabetes Care.

[154]  Craig Wilson,et al.  Alogliptin after acute coronary syndrome in patients with type 2 diabetes. , 2013, The New England journal of medicine.

[155]  Deepak L. Bhatt,et al.  Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. , 2013, The New England journal of medicine.

[156]  Luke Vale,et al.  Relative effectiveness of robot‐assisted and standard laparoscopic prostatectomy as alternatives to open radical prostatectomy for treatment of localised prostate cancer: a systematic review and mixed treatment comparison meta‐analysis , 2013, BJU international.

[157]  J. Rosenstock,et al.  Alogliptin versus glipizide monotherapy in elderly type 2 diabetes mellitus patients with mild hyperglycaemia: a prospective, double‐blind, randomized, 1‐year study , 2013, Diabetes, obesity & metabolism.

[158]  A. Tahrani,et al.  SGLT inhibitors in management of diabetes. , 2013, The lancet. Diabetes & endocrinology.

[159]  A. Hughes,et al.  A randomized placebo controlled double blind crossover study of pioglitazone on left ventricular diastolic function in type 2 diabetes. , 2013, International journal of cardiology.

[160]  J. Rosenstock,et al.  Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin , 2013, Diabetes Care.

[161]  J. Rosenstock,et al.  Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled With Newly Initiated and Continuously Titrated Basal Insulin Glargine , 2013, Diabetes Care.

[162]  J. Rosenstock,et al.  Randomized Trial of Continuous Subcutaneous Delivery of Exenatide by ITCA 650 Versus Twice-Daily Exenatide Injections in Metformin-Treated Type 2 Diabetes , 2013, Diabetes Care.

[163]  Robert Bigelow,et al.  Results of a reevaluation of cardiovascular outcomes in the RECORD trial. , 2013, American heart journal.

[164]  T. Heise,et al.  Safety, tolerability, pharmacokinetics and pharmacodynamics following 4 weeks' treatment with empagliflozin once daily in patients with type 2 diabetes , 2013, Diabetes, obesity & metabolism.

[165]  J. Rosenstock,et al.  Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin , 2013, Diabetes Care.

[166]  C. Bailey.  Interpreting Adverse Signals in Diabetes Drug Development Programs , 2013, Diabetes Care.

[167]  A. Scheen,et al.  Metformin revisited: a critical review of the benefit-risk balance in at-risk patients with type 2 diabetes. , 2013, Diabetes & metabolism.

[168]  F. Folli,et al.  The role of nateglinide and repaglinide, derivatives of meglitinide, in the treatment of type 2 diabetes mellitus , 2013, Archives of medical science : AMS.

[169]  A. Scheen.  Pharmacokinetic considerations for the treatment of diabetes in patients with chronic kidney disease , 2013, Expert opinion on drug metabolism & toxicology.

[170]  M. Marre,et al.  Efficacy and Safety of Sitagliptin Versus Glipizide in Patients With Type 2 Diabetes and Moderate-to-Severe Chronic Renal Insufficiency , 2013, Diabetes Care.

[171]  S. Heller,et al.  Once-Weekly Exenatide Versus Once- or Twice-Daily Insulin Detemir , 2013, Diabetes Care.

[172]  B. Goldstein,et al.  Efficacy and safety of sitagliptin in patients with type 2 diabetes and ESRD receiving dialysis: a 54-week randomized trial. , 2013, American journal of kidney diseases : the official journal of the National Kidney Foundation.

[173]  R. Aronson,et al.  Efficacy and Safety of Lixisenatide Once-Daily Morning or Evening Injections in Type 2 Diabetes Inadequately Controlled on Metformin (GetGoal-M) , 2013, Diabetes Care.

[174]  Daniala L. Weir,et al.  Comparative Safety and Effectiveness of Metformin in Patients With Diabetes Mellitus and Heart Failure: Systematic Review of Observational Studies Involving 34 000 Patients , 2013, Circulation. Heart failure.

[175]  A. D'Angelo,et al.  A randomized, double-blind, comparative therapy evaluating sitagliptin versus glibenclamide in type 2 diabetes patients already treated with pioglitazone and metformin: a 3-year study. , 2013, Diabetes technology & therapeutics.

[176]  A. Scheen,et al.  Cardiovascular effects of gliptins , 2013, Nature Reviews Cardiology.

[177]  W. Sheu,et al.  Exenatide once weekly versus liraglutide once daily in patients with type 2 diabetes (DURATION-6): a randomised, open-label study , 2013, The Lancet.

[178]  Richard Cairns,et al.  A clinical risk score for heart failure in patients with type 2 diabetes and macrovascular disease: an analysis of the PROactive study. , 2013, International journal of cardiology.

[179]  Hsin-Chieh Yeh,et al.  Effect of the 2011 vs 2003 duty hour regulation-compliant models on sleep duration, trainee education, and continuity of patient care among internal medicine house staff: a randomized trial. , 2013, JAMA internal medicine.

[180]  J. Rosenstock,et al.  Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by EstablishedBasal Insulin A 24-week, randomized, placebo-controlled comparison (GetGoal-L) , 2013 .

[181]  S. Hahn,et al.  Differences in the glucose-lowering efficacy of dipeptidyl peptidase-4 inhibitors between Asians and non-Asians: a systematic review and meta-analysis , 2013, Diabetologia.

[182]  J. Meier.  GLP-1 receptor agonists for individualized treatment of type 2 diabetes mellitus , 2012, Nature Reviews Endocrinology.

[183]  J. Bolinder,et al.  Dapagliflozin has no effect on markers of bone formation and resorption or bone mineral density in patients with inadequately controlled type 2 diabetes mellitus on metformin , 2012, Diabetes, obesity & metabolism.

[184]  O. Froy,et al.  Metformin affects the circadian clock and metabolic rhythms in a tissue-specific manner. , 2012, Biochimica et biophysica acta.

[185]  K. Rascati,et al.  Efficacy and Safety of Dipeptidyl Peptidase-4 Inhibitors in Type 2 Diabetes: Meta-Analysis , 2012, The Annals of pharmacotherapy.

[186]  E. Liao.  Management of type 2 diabetes: new and future developments in treatment. , 2012, The American journal of medicine.

[187]  J. Rosenstock,et al.  2-year efficacy and safety of linagliptin compared with glimepiride in patients with type 2 diabetes inadequately controlled on metformin: a randomised, double-blind, non-inferiority trial , 2012, The Lancet.

[188]  C. Deacon,et al.  Glycaemic efficacy of glucagon‐like peptide‐1 receptor agonists and dipeptidyl peptidase‐4 inhibitors as add‐on therapy to metformin in subjects with type 2 diabetes—a review and meta analysis , 2012, Diabetes, obesity & metabolism.

[189]  M. Persson,et al.  Vildagliptin reduces glucagon during hyperglycemia and sustains glucagon counterregulation during hypoglycemia in type 1 diabetes. , 2012, The Journal of clinical endocrinology and metabolism.

[190]  B. Hoogwerf,et al.  Efficacy of GLP-1 receptor agonists and DPP-4 inhibitors: meta-analysis and systematic review. , 2012, Clinical therapeutics.

[191]  S. Schwartz,et al.  Canagliflozin improves glycaemic control over 28 days in subjects with type 2 diabetes not optimally controlled on insulin , 2012, Diabetes, obesity & metabolism.

[192]  J. Holst,et al.  Exenatide reduces reperfusion injury in patients with ST-segment elevation myocardial infarction. , 2012, European heart journal.

[193]  Y. Seino,et al.  Randomized, double-blind, placebo-controlled trial of the once-daily GLP-1 receptor agonist lixisenatide in Asian patients with type 2 diabetes insufficiently controlled on basal insulin with or without a sulfonylurea (GetGoal-L-Asia)* , 2012, Diabetes, obesity & metabolism.

[194]  V. Fonseca,et al.  Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide in Monotherapy , 2012, Diabetes Care.

[195]  Kathryn M. Hurren,et al.  Drug-Drug Interactions with Glucagon-Like Peptide-1 Receptor Agonists , 2012, The Annals of pharmacotherapy.

[196]  B. Hoogwerf,et al.  Baseline Factors Associated With Glycemic Control and Weight Loss When Exenatide Twice Daily Is Added to Optimized Insulin Glargine in Patients With Type 2 Diabetes , 2012, Diabetes Care.

[197]  D. Matthews,et al.  Dipeptidyl peptidase-4 inhibitors for treatment of type 2 diabetes mellitus in the clinical setting: systematic review and meta-analysis , 2012, BMJ : British Medical Journal.

[198]  G. Shulman,et al.  Mechanisms for Insulin Resistance: Common Threads and Missing Links , 2012, Cell.

[199]  B. Viollet,et al.  Cellular and molecular mechanisms of metformin: an overview. , 2012, Clinical science.

[200]  D. Drucker,et al.  Cardiovascular biology of the incretin system. , 2012, Endocrine reviews.

[201]  E. Mohammadi,et al.  Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.

[202]  M. Hanefeld,et al.  Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4) , 2012, Diabetes Care.

[203]  M. Christensen,et al.  Effects of glucagon-like peptide-1 receptor agonists on weight loss: systematic review and meta-analyses of randomised controlled trials , 2012, BMJ : British Medical Journal.

[204]  R. Grempler,et al.  Empagliflozin, a novel selective sodium glucose cotransporter‐2 (SGLT‐2) inhibitor: characterisation and comparison with other SGLT‐2 inhibitors , 2012, Diabetes, obesity & metabolism.

[205]  M. Rendell.  The Role of Sulphonylureas in the Management of Type 2 Diabetes Mellitus , 2012, Drugs.

[206]  C. Bailey,et al.  Oral Antidiabetic Agents , 2012, Drugs.

[207]  V. Fonseca,et al.  Efficacy and Safety of the Once-Daily GLP-1 Receptor Agonist Lixisenatide inMonotherapy A randomized, double-blind, placebo-controlled trial in patients with type 2 diabetes (GetGoal-Mono) , 2012 .

[208]  Gangyi Yang,et al.  Glucagon‐like peptide‐1 receptor agonists versus insulin in inadequately controlled patients with type 2 diabetes mellitus: a meta‐analysis of clinical trials , 2011, Diabetes, obesity & metabolism.

[209]  M. Davies,et al.  Efficacy of antihyperglycemic therapies and the influence of baseline hemoglobin A(1C): a meta-analysis of the liraglutide development program. , 2011, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[210]  P. Brubaker,et al.  Mechanisms underlying metformin-induced secretion of glucagon-like peptide-1 from the intestinal L cell. , 2011, Endocrinology.

[211]  A. Barnett,et al.  Lixisenatide: evidence for its potential use in the treatment of type 2 diabetes , 2011, Core evidence.

[212]  S. Del Prato,et al.  Dapagliflozin Versus Glipizide as Add-on Therapy in Patients With Type 2 Diabetes Who Have Inadequate Glycemic Control With Metformin , 2011, Diabetes Care.

[213]  S. Prato,et al.  Management of type 2 diabetes: new and future developments in treatment , 2011, The Lancet.

[214]  S. Davis,et al.  Pramlintide and the treatment of diabetes: a review of the data since its introduction , 2011, Expert opinion on pharmacotherapy.

[215]  R. Giorgino,et al.  Nateglinide provides tighter glycaemic control than glyburide in patients with Type 2 diabetes with prevalent postprandial hyperglycaemia , 2011, Diabetic medicine : a journal of the British Diabetic Association.

[216]  T. Hardy,et al.  A 5‐week study of the pharmacokinetics and pharmacodynamics of LY2189265, a novel, long‐acting glucagon‐like peptide‐1 analogue, in patients with type 2 diabetes , 2011, Diabetes, obesity & metabolism.

[217]  D. Loo,et al.  Biology of human sodium glucose transporters. , 2011, Physiological reviews.

[218]  B. Bode,et al.  Liraglutide, a once-daily human glucagon-like peptide 1 analogue, provides sustained improvements in glycaemic control and weight for 2 years as monotherapy compared with glimepiride in patients with type 2 diabetes , 2011, Diabetes, obesity & metabolism.

[219]  M. Trautmann,et al.  DURATION-5: exenatide once weekly resulted in greater improvements in glycemic control compared with exenatide twice daily in patients with type 2 diabetes. , 2011, The Journal of clinical endocrinology and metabolism.

[220]  C. Bailey.  Renal glucose reabsorption inhibitors to treat diabetes. , 2011, Trends in pharmacological sciences.

[221]  R. Day,et al.  Clinical Pharmacokinetics of Metformin , 2011, Clinical pharmacokinetics.

[222]  M. S. Lewis,et al.  Use of Twice-Daily Exenatide in Basal Insulin–Treated Patients With Type 2 Diabetes , 2011, Annals of Internal Medicine.

[223]  C. Deacon,et al.  Dipeptidyl peptidase‐4 inhibitors in the treatment of type 2 diabetes: a comparative review , 2011, Diabetes, obesity & metabolism.

[224]  Karl H. Wolf,et al.  Comparative review , 2011, J. Documentation.

[225]  M. Soma,et al.  Antidiabetic agents in patients with chronic kidney disease and end-stage renal disease on dialysis: metabolism and clinical practice. , 2011, Current drug metabolism.

[226]  G. Meneilly.  Effect of repaglinide versus glyburide on postprandial glucose and insulin values in elderly patients with type 2 diabetes. , 2011, Diabetes technology & therapeutics.

[227]  D. Drucker,et al.  Metformin regulates the incretin receptor axis via a pathway dependent on peroxisome proliferator-activated receptor-α in mice , 2011, Diabetologia.

[228]  Y. M. Cho,et al.  New aspects of an old drug: metformin as a glucagon-like peptide 1 (GLP-1) enhancer and sensitiser , 2011, Diabetologia.

[229]  R. Holt,et al.  Bromocriptine: old drug, new formulation and new indication , 2010, Diabetes, obesity & metabolism.

[230]  M. Christensen,et al.  Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes. , 2010, Current opinion in molecular therapeutics.

[231]  G. Charpentier,et al.  Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus , 2010, Diabetes/metabolism research and reviews.

[232]  A. Scheen.  Dipeptidylpeptitase-4 inhibitors (gliptins): focus on drug-drug interactions. , 2010 .

[233]  J. Rosenstock,et al.  Dose-dependent effects of the once-daily GLP-1 receptor agonist lixisenatide in patients with Type 2 diabetes inadequately controlled with metformin: a randomized, double-blind, placebo-controlled trial , 2010, Diabetic medicine : a journal of the British Diabetic Association.

[234]  B. Zinman,et al.  Vildagliptin add‐on to metformin produces similar efficacy and reduced hypoglycaemic risk compared with glimepiride, with no weight gain: results from a 2‐year study , 2010, Diabetes, obesity & metabolism.

[235]  A. Tahrani,et al.  Exenatide once weekly: clinical outcomes and patient satisfaction , 2010, Patient preference and adherence.

[236]  R. Bergenstal,et al.  Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial , 2010, The Lancet.

[237]  G. Rutter,et al.  Hypothalamic AMP-Activated Protein Kinase Regulates Glucose Production , 2010, Diabetes.

[238]  C. Bailey,et al.  SGLT2 inhibitors: glucuretic treatment for type 2 diabetes , 2010 .

[239]  J. Northrup,et al.  Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial , 2010, The Lancet.

[240]  E. Ferrannini,et al.  Dapagliflozin Monotherapy in Type 2 Diabetic Patients With Inadequate Glycemic Control by Diet and Exercise , 2010, Diabetes Care.

[241]  Joseph S. Takahashi,et al.  Disruption of the Clock Components CLOCK and BMAL 1 Leads to Hypoinsulinemia and Diabetes , 2012 .

[242]  Vivian A Fonseca,et al.  Colesevelam lowers glucose and lipid levels in type 2 diabetes: the clinical evidence , 2010, Diabetes, obesity & metabolism.

[243]  J de Lange,et al.  An evidence-based review? , 2010, Journal of oral and maxillofacial surgery : official journal of the American Association of Oral and Maxillofacial Surgeons.

[244]  M. Laakso,et al.  Effect of nateglinide on the incidence of diabetes and cardiovascular events. , 2010, The New England journal of medicine.

[245]  R. Berkowitz,et al.  Faculty Opinions recommendation of Vaginal brachytherapy versus pelvic external beam radiotherapy for patients with endometrial cancer of high-intermediate risk (PORTEC-2): an open-label, non-inferiority, randomised trial. , 2010 .

[246]  M. Davies,et al.  Safety and efficacy of treatment with sitagliptin or glipizide in patients with type 2 diabetes inadequately controlled on metformin: a 2‐year study , 2010, International journal of clinical practice.

[247]  C. O'connor,et al.  Randomized Clinical Trial of Quick-Release Bromocriptine Among Patients With Type 2 Diabetes on Overall Safety and Cardiovascular Outcomes , 2010, Diabetes Care.

[248]  D. Drucker,et al.  DURATION-1: Exenatide Once Weekly Produces Sustained Glycemic Control and Weight Loss Over 52 Weeks , 2010, Diabetes Care.

[249]  M. Christensen,et al.  Once-Weekly GLP-1 Agonists: How Do They Differ from Exenatide and Liraglutide? , 2010, Current diabetes reports.

[250]  W. Humphreys,et al.  In Vitro Characterization and Pharmacokinetics of Dapagliflozin (BMS-512148), a Potent Sodium-Glucose Cotransporter Type II Inhibitor, in Animals and Humans , 2010, Drug Metabolism and Disposition.

[251]  B. Thorens,et al.  Glucose transporters in the 21st Century. , 2010, American journal of physiology. Endocrinology and metabolism.

[252]  A. Tahrani,et al.  Glycaemic control in type 2 diabetes: targets and new therapies. , 2010, Pharmacology & therapeutics.

[253]  B. Hoogwerf,et al.  Effect of exenatide on heart rate and blood pressure in subjects with type 2 diabetes mellitus: a double-blind, placebo-controlled, randomized pilot study , 2010, Cardiovascular diabetology.

[254]  J. Gautier,et al.  A comparison of efficacy and safety of vildagliptin and gliclazide in combination with metformin in patients with Type 2 diabetes inadequately controlled with metformin alone: a 52‐week, randomized study , 2009, Diabetic medicine : a journal of the British Diabetic Association.

[255]  Michael E. Miller,et al.  ACTION TO CONTROL CARDIOVASCULAR RISK IN DIABETES STUDY GROUP. EFFECTS OF INTENSIVE GLUCOSE LOWERING IN TYPE 2 DIABETES , 2010 .

[256]  I. Harris,et al.  A Systematic Review and Meta-Analysis of Randomized Controlled Trials , 2010 .

[257]  U. Boggi,et al.  The beta-cell in human type 2 diabetes. , 2010, Advances in experimental medicine and biology.

[258]  A. Scheen.  Dipeptidylpeptidase-4 Inhibitors (Gliptins) , 2010, Clinical pharmacokinetics.

[259]  J. Holst,et al.  Secretion of glucagon-like peptide-1 (GLP-1) in type 2 diabetes: what is up, what is down? , 2010, Diabetologia.

[260]  O. Pedersen,et al.  Combining insulin with metformin or an insulin secretagogue in non-obese patients with type 2 diabetes: 12 month, randomised, double blind trial , 2009, BMJ : British Medical Journal.

[261]  A. Tahrani,et al.  DPP-4 Inhibitors in Clinical Practice , 2009, Postgraduate medicine.

[262]  J. Foley,et al.  Efficacy and Safety Comparison Between the DPP-4 Inhibitor Vildagliptin and the Sulfonylurea Gliclazide After Two Years of Monotherapy in Drug-naïve Patients with Type 2 Diabetes , 2009, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[263]  A. Vaag,et al.  Liraglutide vs insulin glargine and placebo in combination with metformin and sulfonylurea therapy in type 2 diabetes mellitus (LEAD-5 met+SU): a randomised controlled trial , 2009, Diabetologia.

[264]  J. Holst,et al.  Lixisenatide, a novel GLP-1 receptor agonist for the treatment of type 2 diabetes mellitus. , 2009, IDrugs : the investigational drugs journal.

[265]  J. Rosenstock,et al.  Potential of Albiglutide, a Long-Acting GLP-1 Receptor Agonist, in Type 2 Diabetes , 2009, Diabetes Care.

[266]  J. Rosenstock,et al.  Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6) , 2009, The Lancet.

[267]  J. Geddes,et al.  What is a randomised controlled trial? , 2009, Epidemiologia e Psichiatria Sociale.

[268]  T. Lam,et al.  CNS regulation of glucose homeostasis. , 2009, Physiology.

[269]  L. Groop,et al.  Melatonin receptors in pancreatic islets: good morning to a novel type 2 diabetes gene , 2009, Diabetologia.

[270]  Ralph A. DeFronzo,et al.  From the Triumvirate to the Ominous Octet: A New Paradigm for the Treatment of Type 2 Diabetes Mellitus , 2009, Diabetes.

[271]  A. Tahrani,et al.  Saxagliptin: a new DPP-4 inhibitor for the treatment of type 2 diabetes mellitus , 2009, Advances in therapy.

[272]  A. Tahrani,et al.  Drug evaluation: Vildagliptin-metformin single-tablet combination , 2009, Advances in therapy.

[273]  B. Zinman,et al.  Efficacy and Safety of the Human Glucagon-Like Peptide-1 Analog Liraglutide in Combination With Metformin and Thiazolidinedione in Patients With Type 2 Diabetes (LEAD-4 Met+TZD) , 2009, Diabetes Care.

[274]  S. Colagiuri,et al.  Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU) , 2009, Diabetic medicine : a journal of the British Diabetic Association.

[275]  A. Barnett.  New treatments in type 2 diabetes: a focus on the incretin‐based therapies , 2009, Clinical endocrinology.

[276]  B. Bode,et al.  Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial , 2009, The Lancet.

[277]  Grant D. Huang,et al.  Glucose control and vascular complications in veterans with type 2 diabetes. , 2009, The New England journal of medicine.

[278]  C. Furberg,et al.  Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis , 2009, Canadian Medical Association Journal.

[279]  D. Matthews,et al.  Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes , 2008, Diabetes Care.

[280]  M. Bush,et al.  Pharmacodynamics, pharmacokinetics, safety, and tolerability of albiglutide, a long-acting glucagon-like peptide-1 mimetic, in patients with type 2 diabetes. , 2008, The Journal of clinical endocrinology and metabolism.

[281]  J. Sieradzki,et al.  The efficacy of self‐monitoring of blood glucose in the management of patients with type 2 diabetes treated with a gliclazide modified release–based regimen. A multicentre, randomized, parallel‐group, 6‐month evaluation (DINAMIC 1 study) , 2008, Diabetes, obesity & metabolism.

[282]  R. Holman,et al.  10-year follow-up of intensive glucose control in type 2 diabetes. , 2008, The New England journal of medicine.

[283]  D. Drucker,et al.  Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study , 2008, The Lancet.

[284]  J. Gerich,et al.  Nateglinide, alone or in combination with metformin, is effective and well tolerated in treatment‐naïve elderly patients with type 2 diabetes , 2008, Diabetes, obesity & metabolism.

[285]  T. Lee,et al.  Time for a rethink , 2008, Veterinary Record.

[286]  Michael E. Miller,et al.  Effects of intensive glucose lowering in type 2 diabetes. , 2008, The New England journal of medicine.

[287]  Diederick Grobbee,et al.  Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. , 2008, The New England journal of medicine.

[288]  C. Bailey,et al.  Metformin and the intestine , 2008, Diabetologia.

[289]  A. Barnett.  Treatment intensification in patients with type 2 diabetes , 2008, Diabetes, obesity & metabolism.

[290]  E. Tuzcu,et al.  Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. , 2008, JAMA.

[291]  W. Humphreys,et al.  Discovery of dapagliflozin: a potent, selective renal sodium-dependent glucose cotransporter 2 (SGLT2) inhibitor for the treatment of type 2 diabetes. , 2008, Journal of medicinal chemistry.

[292]  J. Girard,et al.  Physiology of incretins (GIP and GLP-1) and abnormalities in type 2 diabetes. , 2008, Diabetes & metabolism.

[293]  F. Schmidt.  Meta-Analysis , 2008 .

[294]  Marco Ranucci,et al.  A Meta-analysis of Randomized Clinical Trials , 2008 .

[295]  D. Klonoff,et al.  Exenatide effects on diabetes, obesity, cardiovascular risk factors and hepatic biomarkers in patients with type 2 diabetes treated for at least 3 years. , 2008, Current medical research and opinion.

[296]  P. Flatt,et al.  Incretin hormone mimetics and analogues in diabetes therapeutics. , 2007, Best practice & research. Clinical endocrinology & metabolism.

[297]  P. Marchetti,et al.  ß‐cell function and anti‐diabetic pharmacotherapy , 2007 .

[298]  A. Tahrani,et al.  Metformin, heart failure, and lactic acidosis: is metformin absolutely contraindicated? , 2007, BMJ : British Medical Journal.

[299]  B. Viollet,et al.  Activation of 5′-AMP-activated Kinase with Diabetes Drug Metformin Induces Casein Kinase Iϵ (CKIϵ)-dependent Degradation of Clock Protein mPer2* , 2007, Journal of Biological Chemistry.

[300]  S. Nissen,et al.  Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. , 2007, The New England journal of medicine.

[301]  D. Drucker,et al.  Biology of incretins: GLP-1 and GIP. , 2007, Gastroenterology.

[302]  A. Skene,et al.  The effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction: results from the PROactive (PROactive 05) Study. , 2007, Journal of the American College of Cardiology.

[303]  P. Royle,et al.  Meglitinide analogues for type 2 diabetes mellitus. , 2007, The Cochrane database of systematic reviews.

[304]  P. Kothare,et al.  Effect of renal impairment on the pharmacokinetics of exenatide , 2007, British journal of clinical pharmacology.

[305]  C. Bailey.  Treating insulin resistance: future prospects , 2007, Diabetes & vascular disease research.

[306]  D. Betteridge,et al.  Effects of Pioglitazone in Patients With Type 2 Diabetes With or Without Previous Stroke: Results From PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04) , 2007, Stroke.

[307]  E. Wright,et al.  Active sugar transport in health and disease , 2007, Journal of internal medicine.

[308]  A. Scheen.  Drug-Drug and Food-Drug Pharmacokinetic Interactions with New Insulinotropic Agents Repaglinide and Nateglinide , 2007, Clinical pharmacokinetics.

[309]  P. Marchetti,et al.  beta-cell function and anti-diabetic pharmacotherapy. , 2007, Diabetes/metabolism research and reviews.

[310]  A. Scheen.  Pharmacokinetic Interactions with Thiazolidinediones , 2007, Clinical pharmacokinetics.

[311]  J. Holst,et al.  Pharmacokinetics and Pharmacodynamics of Vildagliptin in Patients with Type 2 Diabetes Mellitus , 2007, Clinical pharmacokinetics.

[312]  UK Prospective Diabetes Study Group.  Risk of hypoglycaemia in types 1 and 2 diabetes: effects of treatment modalities and their duration , 2007, Diabetologia.

[313]  P. Mahadevan,et al.  An overview , 2007, Journal of Biosciences.

[314]  S. Kahn,et al.  Mechanisms linking obesity to insulin resistance and type 2 diabetes , 2006, Nature.

[315]  B. Zinman,et al.  Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy. , 2006, The New England journal of medicine.

[316]  S. Haffner,et al.  Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. , 2006, JAMA.

[317]  D. Drucker,et al.  The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes , 2006, The Lancet.

[318]  Richard Mateosian,et al.  Old and New , 2006, IEEE Micro.

[319]  A. Young,et al.  Investigation of exenatide elimination and its in vivo and in vitro degradation. , 2006, Current drug metabolism.

[320]  J. Holst,et al.  Exendin-4, but not glucagon-like peptide-1, is cleared exclusively by glomerular filtration in anaesthetised pigs , 2006, Diabetologia.

[321]  W. Zeng,et al.  Pharmacokinetics and pharmacodynamics of sitagliptin, an inhibitor of dipeptidyl peptidase IV, in healthy subjects: Results from two randomized, double‐blind, placebo‐controlled studies with single oral doses , 2005, Clinical pharmacology and therapeutics.

[322]  Erland Erdmann,et al.  Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.

[323]  I. Campbell.  Nateglinide – current and future role in the treatment of patients with type 2 diabetes mellitus , 2005, International journal of clinical practice.

[324]  Nimesh Mody,et al.  Serum retinol binding protein 4 contributes to insulin resistance in obesity and type 2 diabetes , 2005, Nature.

[325]  A. Sanabria,et al.  Randomized controlled trial. , 2005, World journal of surgery.

[326]  A. Panelo,et al.  Repaglinide/bedtime NPH insulin is comparable to twice-daily NPH insulin. , 2005, Diabetes care.

[327]  J. Terdiman,et al.  Effect of 5-Aminosalicylate Use on Colorectal Cancer and Dysplasia Risk: A Systematic Review and Metaanalysis of Observational Studies , 2005, The American Journal of Gastroenterology.

[328]  Michael Brownlee,et al.  The pathobiology of diabetic complications: a unifying mechanism. , 2005, Diabetes.

[329]  M. Hanefeld,et al.  Long-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetes , 2005, Diabetologia.

[330]  K. Wellen,et al.  Inflammation, stress, and diabetes. , 2005, The Journal of clinical investigation.

[331]  P. Flatt,et al.  Inhibition of dipeptidyl peptidase IV activity by oral metformin in Type 2 diabetes , 2005, Diabetic medicine : a journal of the British Diabetic Association.

[332]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control over 30 weeks in patients with type 2 diabetes treated with metformin and a sulfonylurea. , 2005, Diabetes care.

[333]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. , 2005, Diabetes care.

[334]  Michael Stumvoll,et al.  Type 2 diabetes: principles of pathogenesis and therapy , 2005, The Lancet.

[335]  M. Nauck,et al.  The therapeutic actions of DPP-IV inhibition are not mediated by glucagon-like peptide-1 , 2005, Diabetologia.

[336]  Dennis D. Kim,et al.  Pharmacokinetics, pharmacodynamics, and safety of exenatide in patients with type 2 diabetes mellitus. , 2005, American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists.

[337]  I. Dicembrini,et al.  Effects of metformin on glucagon-like peptide-1 levels in obese patients with and without Type 2 diabetes. , 2004, Diabetes, nutrition & metabolism.

[338]  A. Jacobson.  Impact of improved glycemic control on quality of life in patients with diabetes. , 2004, Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists.

[339]  Dennis D. Kim,et al.  Effects of exenatide (exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes. , 2004, Diabetes care.

[340]  A. Novials,et al.  GUIDE study: double‐blind comparison of once‐daily gliclazide MR and glimepiride in type 2 diabetic patients , 2004, European journal of clinical investigation.

[341]  J. Rosenstock,et al.  Repaglinide versus nateglinide monotherapy: a randomized, multicenter study. , 2004, Diabetes care.

[342]  B. Cheung,et al.  Meta-analysis of large randomized controlled trials to evaluate the impact of statins on cardiovascular outcomes. , 2004, British journal of clinical pharmacology.

[343]  J. Henquin.  The fiftieth anniversary of hypoglycaemic sulphonamides. How did the mother compound work? , 1992, Diabetologia.

[344]  Thomas R. Riley,et al.  A Randomized Double-blind Placebo-controlled Trial , 2004 .

[345]  Abdulmajeed Al Abdukareem.  Randomized, placebo-controlled trial , 2004, Annals of Saudi medicine.

[346]  C. van Weel,et al.  Is acarbose equivalent to tolbutamide as first treatment for newly diagnosed type 2 diabetes in general practice? A randomised controlled trial. , 2004, Diabetes research and clinical practice.

[347]  B. Ahrén.  Gut peptides and type 2 diabetes mellitus treatment , 2003, Current Diabetes Reports.

[348]  P. Grant,et al.  Beneficial effects of metformin on haemostasis and vascular function in man. , 2003, Diabetes & metabolism.

[349]  W. März,et al.  Pioglitazone reduces atherogenic dense LDL particles in nondiabetic patients with arterial hypertension: a double-blind, placebo-controlled study. , 2003, Diabetes care.

[350]  Markolf Hanefeld,et al.  Acarbose treatment and the risk of cardiovascular disease and hypertension in patients with impaired glucose tolerance: the STOP-NIDDM trial. , 2003, JAMA.

[351]  D. Drucker.  Glucagon-like peptides: regulators of cell proliferation, differentiation, and apoptosis. , 2003, Molecular endocrinology.

[352]  E. Salpeter,et al.  Risk of fatal and nonfatal lactic acidosis with metformin use in type 2 diabetes mellitus. , 2003, The Cochrane database of systematic reviews.

[353]  M. White,et al.  SOCS-1 and SOCS-3 Block Insulin Signaling by Ubiquitin-mediated Degradation of IRS1 and IRS2* , 2002, The Journal of Biological Chemistry.

[354]  J. Sturis,et al.  Pharmacokinetics, pharmacodynamics, safety, and tolerability of a single-dose of NN2211, a long-acting glucagon-like peptide 1 derivative, in healthy male subjects. , 2002, Diabetes care.

[355]  M. Laakso,et al.  Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial , 2002, The Lancet.

[356]  W. Canovatchel,et al.  Pharmacokinetics and Pharmacodynamics of Extended‐Release Glipizide GITS Compared with Immediate‐Release Glipizide in Patients with Type II Diabetes Mellitus , 2002, Journal of clinical pharmacology.

[357]  J. Rosenstock,et al.  EFFICACY AND SAFETY OF PIOGLITAZONE IN TYPE 2 DIABETES: A RANDOMISED, PLACEBO‐CONTROLLED STUDY IN PATIENTS RECEIVING STABLE INSULIN THERAPY , 2002, International journal of clinical practice.

[358]  H. Hauner.  The mode of action of thiazolidinediones , 2002, Diabetes/metabolism research and reviews.

[359]  J. Sturis,et al.  Bedtime administration of NN2211, a long-acting GLP-1 derivative, substantially reduces fasting and postprandial glycemia in type 2 diabetes. , 2002, Diabetes.

[360]  J. Sturis,et al.  Bedtime Administration of NN 2211 , a Long-Acting GLP-1 Derivative , Substantially Reduces Fasting and Postprandial Glycemia in Type 2 Diabetes , 2002 .

[361]  M. Zdravkovic,et al.  The pharmacokinetics, pharmacodynamics, safety and tolerability of NN2211, a new long-acting GLP-1 derivative, in healthy men , 2002, Diabetologia.

[362]  A. Dornhorst.  Insulinotropic meglitinide analogues , 2001, The Lancet.

[363]  Margaret S. Wu,et al.  Role of AMP-activated protein kinase in mechanism of metformin action. , 2001, The Journal of clinical investigation.

[364]  D. Hörsch,et al.  Glucose-dependent insulinotropic polypeptide is a growth factor for beta (INS-1) cells by pleiotropic signaling. , 2001, Molecular endocrinology.

[365]  K. Freedland,et al.  Association of Depression and Diabetes Complications: A Meta-Analysis , 2001, Psychosomatic medicine.

[366]  G. Frost,et al.  Exendin-4 reduces fasting and postprandial glucose and decreases energy intake in healthy volunteers. , 2001, American journal of physiology. Endocrinology and metabolism.

[367]  S. Madsbad,et al.  Comparison between repaglinide and glipizide in Type 2 diabetes mellitus: a 1‐year multicentre study , 2001, Diabetic medicine : a journal of the British Diabetic Association.

[368]  E. Mannucci,et al.  Effect of metformin on glucagon-like peptide 1 (GLP-1) and leptin levels in obese nondiabetic subjects. , 2001, Diabetes care.

[369]  E. Wright,et al.  Renal Na(+)-glucose cotransporters. , 2001, American journal of physiology. Renal physiology.

[370]  A. Creutzig,et al.  [Clinical evidence]. , 2001, VASA. Zeitschrift fur Gefasskrankheiten.

[371]  R. Schmitz,et al.  Pancreatic β-Cell KATP Channel Activity and Membrane-Binding Studies with Nateglinide: A Comparison with Sulfonylureas and Repaglinide , 2000, The Journal of Pharmacology and Experimental Therapeutics.

[372]  M. Wolfe,et al.  GIP biology and fat metabolism. , 1999, Life sciences.

[373]  Rolf Mentlein,et al.  Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides , 1999, Regulatory Peptides.

[374]  A. Cincotta,et al.  Bromocriptine improves glycaemic control and serum lipid profile in obese Type 2 diabetic subjects: a new approach in the treatment of diabetes. , 1999, Expert opinion on investigational drugs.

[375]  F. Ashcroft,et al.  ATP-sensitive K+ channels and insulin secretion: their role in health and disease , 1999, Diabetologia.

[376]  H. Lebovitz,et al.  Repaglinide versus glyburide: a one-year comparison trial. , 1999, Diabetes research and clinical practice.

[377]  J. Holst,et al.  Glucagon-like peptide-1-(7-36)amide is transformed to glucagon-like peptide-1-(9-36)amide by dipeptidyl peptidase IV in the capillaries supplying the L cells of the porcine intestine. , 1999, Endocrinology.

[378]  R. Holman,et al.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. , 1998 .

[379]  R. Holman,et al.  Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34) , 1998, The Lancet.

[380]  P. Rothwell,et al.  Meta-analysis of randomised controlled trials , 1997, The Lancet.

[381]  B. Göke,et al.  Cell and molecular biology of the incretin hormones glucagon-like peptide-I and glucose-dependent insulin releasing polypeptide. , 1995, Endocrine reviews.

[382]  E. Araki,et al.  Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus: a randomized prospective 6-year study. , 1995, Diabetes research and clinical practice.

[383]  J. Holst,et al.  Degradation of glucagon-like peptide-1 by human plasma in vitro yields an N-terminally truncated peptide that is a major endogenous metabolite in vivo. , 1995, The Journal of clinical endocrinology and metabolism.

[384]  康生 大久保,et al.  Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin-dependent diabetes mellitus : a randomized prospective 6-year study , 1995 .

[385]  S. Genuth,et al.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. , 1993, The New England journal of medicine.

[386]  Carlson Rf,et al.  Efficacy and safety of reformulated, micronized glyburide tablets in patients with non-insulin-dependent diabetes mellitus: a multicenter, double-blind, randomized trial. , 1993 .

[387]  W. Isley,et al.  Efficacy and safety of reformulated, micronized glyburide tablets in patients with non-insulin-dependent diabetes mellitus: a multicenter, double-blind, randomized trial. , 1993, Clinical therapeutics.

[388]  L. Groop.  Sulfonylureas in NIDDM , 1992, Diabetes Care.

[389]  J. Raufman,et al.  Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Further evidence for an exendin receptor on dispersed acini from guinea pig pancreas. , 1992, The Journal of biological chemistry.

[390]  P. Myllynen,et al.  A RANDOMISED CLINICAL TRIAL , 1989 .

[391]  D. Drucker,et al.  Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[392]  N. Laird,et al.  Meta-analysis in clinical trials. , 1986, Controlled clinical trials.

[393]  R. Eaton,et al.  Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. , 1986, The Journal of clinical endocrinology and metabolism.

[394]  J S Oxford,et al.  Future prospects. , 2021, British medical bulletin.

[395]  K. Johnson.  An Update. , 1984, Journal of food protection.

[396]  A. Barnett,et al.  Effect of bromocriptine on maturity onset diabetes. , 1980, Postgraduate medical journal.

[397]  J. Brown,et al.  Stimulation of insulin secretion by gastric inhibitory polypeptide in man. , 1973, The Journal of clinical endocrinology and metabolism.

[398]  C. Meinert,et al.  A study of the effects of hypoglycemic agents on vascular complications in patients with adult-onset diabetes. II. Mortality results. , 1970, Diabetes.

[399]  H. Elrick,et al.  PLASMA INSULIN RESPONSE TO ORAL AND INTRAVENOUS GLUCOSE ADMINISTRATION. , 1964, The Journal of clinical endocrinology and metabolism.

[400]  C E NEWELL,et al.  The small intestine. , 1951, The Journal of the Tennessee State Medical Association. Tennessee State Medical Association.

[401]  I. Deary,et al.  Insulin resistance , 1996 .